Edmond DE Rothschild Holding S.A. increased its position in Eli Lilly and Company (NYSE:LLY) by 92.7% during the first quarter, Holdings Channel reports. The firm owned 10,355 shares of the company’s stock after buying an additional 4,980 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in Eli Lilly and were worth $871,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the company. Prospera Financial Services Inc boosted its position in Eli Lilly and by 6.7% in the first quarter. Prospera Financial Services Inc now owns 14,258 shares of the company’s stock worth $1,208,000 after buying an additional 895 shares during the period. Alpha Windward LLC boosted its position in Eli Lilly and by 2.0% in the first quarter. Alpha Windward LLC now owns 2,251 shares of the company’s stock worth $189,000 after buying an additional 44 shares during the period. Private Trust Co. NA boosted its position in Eli Lilly and by 43.5% in the first quarter. Private Trust Co. NA now owns 7,787 shares of the company’s stock worth $654,000 after buying an additional 2,360 shares during the period. Verde Servicos Internacionais S.A. bought a new position in Eli Lilly and during the first quarter worth about $10,598,000. Finally, TNB Financial bought a new position in Eli Lilly and during the first quarter worth about $430,000. 75.61% of the stock is currently owned by institutional investors.

Shares of Eli Lilly and Company (NYSE LLY) traded up 0.18% during midday trading on Friday, hitting $81.68. 743,227 shares of the stock traded hands. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $86.72. The company’s 50-day moving average is $83.00 and its 200 day moving average is $81.69. The firm has a market capitalization of $86.17 billion, a PE ratio of 35.34 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.86 earnings per share. Analysts anticipate that Eli Lilly and Company will post $4.16 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be given a dividend of $0.52 per share. The ex-dividend date is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a yield of 2.54%. Eli Lilly and’s dividend payout ratio (DPR) is 90.04%.

ILLEGAL ACTIVITY NOTICE: “Eli Lilly and Company (LLY) Shares Bought by Edmond DE Rothschild Holding S.A.” was reported by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/eli-lilly-and-company-lly-shares-bought-by-edmond-de-rothschild-holding-s-a/1475322.html.

Several equities analysts recently weighed in on LLY shares. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $100.00 price target on shares of Eli Lilly and in a research report on Monday, April 17th. Cowen and Company raised their price target on shares of Eli Lilly and from $85.00 to $95.00 and gave the company an “outperform” rating in a research report on Monday, April 17th. Morgan Stanley cut shares of Eli Lilly and from an “overweight” rating to an “equal weight” rating and set a $82.00 price target on the stock. in a research report on Monday, April 17th. BMO Capital Markets cut shares of Eli Lilly and from a “market perform” rating to an “underperform” rating and dropped their price target for the company from $73.00 to $71.00 in a research report on Monday, April 17th. Finally, Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price target on the stock in a research report on Monday, July 17th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $88.27.

In related news, insider Melissa S. Barnes sold 1,900 shares of the stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $80.78, for a total transaction of $153,482.00. Following the transaction, the insider now owns 14,041 shares in the company, valued at $1,134,231.98. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Michael J. Harrington sold 22,833 shares of the stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the transaction, the vice president now owns 62,056 shares in the company, valued at approximately $4,962,618.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 669,733 shares of company stock worth $55,845,287. 0.20% of the stock is owned by insiders.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.